MK-8245 is a potent and selective inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which plays a key role in regulating cortisol levels within tissues. By inhibiting this enzyme, MK-8245 reduces local cortisol production, particularly in metabolic tissues such as liver and adipose tissue. This mechanism is being explored for the treatment of metabolic disorders including type 2 diabetes and obesity, where elevated tissue cortisol activity contributes to insulin resistance and dyslipidemia.

The compound has been investigated in preclinical and early clinical studies for its potential to improve glucose homeostasis and reduce hepatic glucose output without affecting systemic cortisol levels, thereby minimizing the risk of adrenal insufficiency. Its tissue-selective action makes it a candidate for targeting metabolic syndrome components with a potentially favorable safety profile. Research on MK-8245 supports the broader development of 11β-HSD1 inhibitors as a novel therapeutic approach in metabolic disease management.